Immunogenicity of The Oral Live Attenuated Human Rotavirus Vaccine RIX4414 (Rotarix? Oral Suspension (Liquid Formulation) Co-administered with Childhood Vaccinations in Panama

摘要

Background: The lyophilized formulation of GlaxoSmithKline's oral, live attenuated human rotavirus vaccine RIX4414(Rotarix?) has shown to be immunogenic in various phase III trials in Europe and Latin America. A phase III, open-label, randomized, study(107077/NCT00363545) was conducted in Panama to assess the immunogenicity of two doses of RIX4414 oral suspension (liquid formulation) to that of the lyophilised formulation with routine vaccinations given concomitantly.